Longitudinal analyses of the innate immune system, including the earliest time points, are essential to understand the immunopathogenesis and clinical course of coronavirus disease (COVID-19). Here, we performed a detailed characterization of natural killer (NK) cells in 205 patients (403 samples; days 2 to 41 after symptom onset) from four independent cohorts using single-cell transcriptomics and proteomics together with functional studies. We found elevated interferon (IFN)-α plasma levels in early severe COVD-19 alongside increased NK cell expression of IFN-stimulated genes (ISGs) and genes involved in IFN-α signaling, while upregulation of tumor necrosis factor (TNF)-induced genes was observed in moderate diseases. NK cells exert anti-SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) activity but are functionally impaired in severe COVID-19. Further, NK cell dysfunction may be relevant for the development of fibrotic lung disease in severe COVID-19, as NK cells exhibited impaired anti-fibrotic activity. Our study indicates preferential IFN-α and TNF responses in severe and moderate COVID-19, respectively, and associates a prolonged IFN-α-induced NK cell response with poorer disease outcome.
- Krämer, B.
- Knoll, R.
- Bonaguro, L.
- ToVinh, M.
- Raabe, J.
- Astaburuaga-García, R.
- Schulte-Schrepping, J.
- Kaiser, K. M.
- Rieke, G. J.
- Bischoff, J.
- Monin, M. B.
- Hoffmeister, C.
- Schlabe, S.
- De Domenico, E.
- Reusch, N.
- Händler, K.
- Reynolds, G.
- Blüthgen, N.
- Hack, G.
- Finnemann, C.
- Nischalke, H. D.
- Strassburg, C. P.
- Stephenson, E.
- Su, Y.
- Gardner, L.
- Yuan, D.
- Chen, D.
- Goldman, J.
- Rosenstiel, P.
- Schmidt, S. V.
- Latz, E.
- Hrusovsky, K.
- Ball, A. J.
- Johnson, J. M.
- Koenig, P. A.
- Schmidt, F. I.
- Haniffa, M.
- Heath, J. R.
- Kümmerer, B. M.
- Keitel, V.
- Jensen, B.
- Stubbemann, P.
- Kurth, F.
- Sander, L. E.
- Sawitzki, B.
- Aschenbrenner, A. C.
- Schultze, J. L.
- Nattermann, J.
Keywords
- Covid-19
- NK cells
- Tnf
- antiviral
- lung fibrosis
- moderate
- proteomics
- scRNA-seq
- severe
- type 1 IFN
- Dioscure Therapeutics SE. F.I.S. is a consultant and shareholder of IFM
- Therapeutics. J.R.H. is founder and board member of Isoplexis and PACT Pharma.
- J.D.G. declares contracted research with Gilead, Lilly, and Regeneron. K.H., J.M.J.,
- and A.J.B. work at Quanterix Corporation. All other authors declare no competing
- interests.